[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2022005086A - Anticuerpos anti-cd73 inmunomoduladores y usos de estos. - Google Patents

Anticuerpos anti-cd73 inmunomoduladores y usos de estos.

Info

Publication number
MX2022005086A
MX2022005086A MX2022005086A MX2022005086A MX2022005086A MX 2022005086 A MX2022005086 A MX 2022005086A MX 2022005086 A MX2022005086 A MX 2022005086A MX 2022005086 A MX2022005086 A MX 2022005086A MX 2022005086 A MX2022005086 A MX 2022005086A
Authority
MX
Mexico
Prior art keywords
antibodies
subject
inter alia
compositions
methods
Prior art date
Application number
MX2022005086A
Other languages
English (en)
Inventor
Richard A Miller
Stephen Willingham
Andrew Hotson
Original Assignee
Corvus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corvus Pharmaceuticals Inc filed Critical Corvus Pharmaceuticals Inc
Publication of MX2022005086A publication Critical patent/MX2022005086A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Los anticuerpos anti-CD73, las composiciones y los métodos proporcionados en la presente permiten, entre otras cosas, el tratamiento de cáncer y enfermedades infecciosas (por ejemplo, bacterianas, virales, micóticas, parasitarias) y la generación de anticuerpos específicos de antígeno in vivo en un sujeto. Los solicitantes han encontrado sorprendentemente que la administración de un anticuerpo anti-CD73 (por ejemplo, CPI-006) a un sujeto induce la diferenciación de las células B y la expansión robusta de clones de células B específicos en el sujeto. Los métodos y composiciones proporcionados en la presente son, entre otras cosas, útiles para una variedad de aplicaciones, incluida la medicina personalizada.
MX2022005086A 2019-11-01 2020-11-02 Anticuerpos anti-cd73 inmunomoduladores y usos de estos. MX2022005086A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962929650P 2019-11-01 2019-11-01
US202063014015P 2020-04-22 2020-04-22
US202063078792P 2020-09-15 2020-09-15
PCT/US2020/058555 WO2021087463A1 (en) 2019-11-01 2020-11-02 Immunomodulatory anti-cd73 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2022005086A true MX2022005086A (es) 2022-08-11

Family

ID=75715383

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005086A MX2022005086A (es) 2019-11-01 2020-11-02 Anticuerpos anti-cd73 inmunomoduladores y usos de estos.

Country Status (8)

Country Link
US (1) US20240218073A1 (es)
EP (1) EP4051713A4 (es)
JP (1) JP2022554285A (es)
KR (1) KR20220107196A (es)
AU (1) AU2020373124A1 (es)
CA (1) CA3159196A1 (es)
MX (1) MX2022005086A (es)
WO (1) WO2021087463A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023509448A (ja) 2020-01-03 2023-03-08 インサイト・コーポレイション 抗ｃｄ７３抗体及びその使用
CN115551595A (zh) 2020-01-03 2022-12-30 因赛特公司 Cd73抑制剂和a2a/a2b腺苷受体抑制剂组合疗法
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012012736A2 (en) * 2010-07-23 2012-01-26 The Ohio State University Method of treating a viral infection dysfunction by disrupting an adenosine receptor pathway
JP7391510B2 (ja) * 2015-12-09 2023-12-05 コーバス・ファーマシューティカルズ・インコーポレイテッド ヒト化抗ｃｄ７３抗体
EP3606962A4 (en) * 2017-04-04 2020-12-23 Corvus Pharmaceuticals, Inc. TREATMENT METHODS FOR HIGH CD73 TUMORS
JP2023538369A (ja) * 2020-08-17 2023-09-07 アケソ バイオファーマ カンパニー，リミティド 抗ｃｄ７３抗体とその使用

Also Published As

Publication number Publication date
CA3159196A1 (en) 2021-05-06
JP2022554285A (ja) 2022-12-28
KR20220107196A (ko) 2022-08-02
WO2021087463A1 (en) 2021-05-06
EP4051713A4 (en) 2024-05-01
EP4051713A1 (en) 2022-09-07
US20240218073A1 (en) 2024-07-04
AU2020373124A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
MX2022005086A (es) Anticuerpos anti-cd73 inmunomoduladores y usos de estos.
EA202190295A1 (ru) Т-клетки с химерным антигенным рецептором, происходящие от плюрипотентных стволовых клеток, полученных посредством иммуноинженерии
AU2019293244A8 (en) Personalized cancer vaccine epitope selection
EP4427739A3 (en) Methods of preparing lipid nanoparticles
MX2021007368A (es) Anticuerpos anti-receptor de transferrina y usos de los mismos.
MX2019008413A (es) Celulas pluripotentes inmunodiseñadas.
MX363307B (es) Plataformas para suministro de antigenos.
NZ706189A (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
WO2019002512A3 (en) GLYCOPROTEINS CUSTOMIZED FROM ENGINEERING AND FULLY FUNCTIONAL
EP4269560A3 (en) Modified epidermal growth factor receptor peptides for use in genetically-modified cells
WO2010104749A3 (en) Antigen presenting cell targeted cancer vaccines
MX2016007865A (es) Peptidos citotoxicos y conjugados de los mismos.
IN2014DN10288A (es)
GB201013215D0 (en) Expression of antibody or a fragment thereof in lactobacillus
JOP20220092A1 (ar) جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر
MX2022005389A (es) Terapia de celulas t con receptor de antigeno quimerico.
MX2021005085A (es) Formulacion de anticuerpo.
MY197735A (en) Pharmaceutical combinations comprising an anti-ly75 antibody
MX2014001626A (es) Preservacion asistida con vacio de productos biologicos, en particular de vacunas.
WO2020132658A3 (en) Tubulysins and protein-tubulysin conjugates
MX2021005421A (es) Macrólidos de 13 miembros con sustitución cíclica en c10 y usos de los mismos.
MX2016014868A (es) Metodos para secar por congelacion y rehidratar productos biologicos.
EP4316497A3 (en) Mesenchymal stem cells as vaccine adjuvants and methods for using the same
WO2018232353A3 (en) BACTERIAL VACCINE
MX2021007047A (es) Formulaciones de anticuerpos.